Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms

Inclusion Criteria: * Age 18-75 years * Male or female * H. pylori negative status * Suffering from nighttime and daytime heartburn for the last ≥3 months * At least 28 days of PPI use prior to study entry * Patients have to be current PPI users with either: * Category 1): ≥ 2 HB episodes in 7 consecutive days, at least one during the nighttime to approved PPI doses, or * Category 2): only obtaining complete relief of GERD symptoms following the addition of acid suppressive agents (e.g. H2RA, additional PPI dose), or antacid therapy, to the approved PPI dose. * Reporting of ≥ 3 HB episodes in 7 consecutive days, at least two during the nighttime, w/o medical treatment during a screening period of up to 21 days (report is based on a daily diary during the screening period) and for Category 1 patients, at least one more HB episode as compared to single dose treatment period. * Use of acceptable form of birth control in females with child-bearing potential * Can swallow a size "00" capsule without difficulty * Willing to comply with study protocol * Understood and signed an informed consent form for this study Exclusion Criteria: * BMI \> 40 * Slow or poor Omeprazole metabolizers (heterozygous or homozygous, respectively based on CYP2C19 genotyping test. * Any significant history of / or concurrent gastrointestinal diseases or conditions including: * Acute gastrointestinal bleeding. or history of GI bleeding within 6 months prior to randomization * Zollinger Ellison Synd…